Use of inhaled/nebulised ipratropium bromide in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2-agonist and systemic steroid in the management of acute asthma exacerbations: a systematic review and meta-analysis of randomised controlled trials
- 12 November 2025
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (3) , 211-218
Abstract
Background: The role of inhaled/nebulised ipratropium bromide (IB) in asthma is unclear. Aims: To assess the efficacy and safety of inhaled/nebulised IB for asthma management in children. Methods: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials and the Web of Science until July 2024. We included randomised controlled trials (RCTs) and followed international guidelines for reporting systematic reviews. Outcomes included morbidity, escalation of care, length of hospital stay, mortality, adverse events and lung function. Results: We included 24 studies (total participants n=3238). The hospitalisation rate (risk ratio (RR) 0.84, 95% CI 0.70 to 1.00, I ² 30%), hospital stay in hours (MD 1.75, 95% CI −0.87 to 4.36, I ² 15%) and paediatric intensive care (PICU) admission (RR 0.91, 95% CI 0.35 to 2.32, I ² 0%) were similar. The hospitalisation rate was lower in patients who received IB nebuliser (RR 0.76, 95% CI 0.64 to 0.90, I ² 0%). The asthma severity score was significantly better in the IB group (MD −0.38, 95% CI −0.63 to −0.12, I 2 59%). No serious adverse events were reported. Conclusion: This review found high-certainty evidence that the IB nebuliser leads to a lower hospitalisation rate. However, when inhaled/nebulised IBs were analysed together, the hospitalisation rate was similar, with moderate certainty evidence. IB improved asthma clinical scores, with low certainty evidence. No difference was reported in other prespecified outcomes. Considering the current evidence and safety profile, inhaled/nebulised IB needs to be considered as an additional treatment for acute asthma exacerbation. PROSPERO registration number: CRD42023405023.Keywords
This publication has 22 references indexed in Scilit:
- Randomized pilot trial of ipratropium versus placebo in children with critical asthmaPediatric Pulmonology, 2020
- Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007Journal of Allergy and Clinical Immunology, 2007
- Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthmaIndian Journal of Pediatrics, 2006
- Nebulized salbutamol vs salbutamol and ipratropium combination in asthmaIndian Journal of Pediatrics, 2004
- Randomized Trial of the Addition of Ipratropium Bromide to Albuterol and Corticosteroid Therapy in Children Hospitalized Because of an Acute Asthma ExacerbationArchives of Pediatrics & Adolescent Medicine, 2001
- Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthmaThe Journal of Pediatrics, 1998
- Efficacy of Nebulized Ipratropium in Severely Asthmatic ChildrenAnnals of Emergency Medicine, 1997
- Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthmaThe Journal of Pediatrics, 1995
- Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in childrenJournal of Allergy and Clinical Immunology, 1988
- Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthmaThe Journal of Pediatrics, 1985